Free Trial

Veradigm (MDRX) Competitors

Veradigm logo
$4.68 -0.07 (-1.47%)
As of 08/7/2025 03:59 PM Eastern

MDRX vs. OMCL, HSTM, CRTX, CNGL, OMQS, KBNT, BLIV, DAIC, SAIC, and RAMP

Should you be buying Veradigm stock or one of its competitors? The main competitors of Veradigm include Omnicell (OMCL), HealthStream (HSTM), Cortexyme (CRTX), Canna-Global Acquisition (CNGL), OMNIQ (OMQS), Kubient (KBNT), Belive (BLIV), CID Holdco (DAIC), Science Applications International (SAIC), and LiveRamp (RAMP).

Veradigm vs. Its Competitors

Veradigm (NASDAQ:MDRX) and Omnicell (NASDAQ:OMCL) are both small-cap health care technology companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

In the previous week, Omnicell had 10 more articles in the media than Veradigm. MarketBeat recorded 11 mentions for Omnicell and 1 mentions for Veradigm. Omnicell's average media sentiment score of 0.60 beat Veradigm's score of 0.00 indicating that Omnicell is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veradigm
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Omnicell
4 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Omnicell has a net margin of 2.01% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.27% beat Veradigm's return on equity.

Company Net Margins Return on Equity Return on Assets
VeradigmN/A N/A N/A
Omnicell 2.01%4.27%2.44%

97.7% of Omnicell shares are owned by institutional investors. 2.3% of Veradigm shares are owned by company insiders. Comparatively, 2.5% of Omnicell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Omnicell has lower revenue, but higher earnings than Veradigm.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veradigm$1.53B0.33N/AN/AN/A
Omnicell$1.11B1.31$12.53M$0.5062.06

Veradigm has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.

Veradigm presently has a consensus price target of $13.00, suggesting a potential upside of 177.78%. Omnicell has a consensus price target of $45.33, suggesting a potential upside of 46.10%. Given Veradigm's higher possible upside, analysts plainly believe Veradigm is more favorable than Omnicell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veradigm
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Omnicell
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

Summary

Omnicell beats Veradigm on 11 of the 13 factors compared between the two stocks.

Get Veradigm News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDRX vs. The Competition

MetricVeradigmComputer integrated systems design IndustryBusiness SectorNASDAQ Exchange
Market Cap$506.68M$1.21B$20.73B$9.57B
Dividend YieldN/A2.65%2.83%4.18%
P/E RatioN/A1.9627.4525.14
Price / Sales0.330.3667.36103.02
Price / CashN/A9.4428.1858.58
Price / BookN/A3.395.655.59
Net IncomeN/A$223.79M$197.12M$265.48M
7 Day Performance-3.51%3.25%1.71%1.22%
1 Month Performance11.16%-0.62%-2.69%0.39%
1 Year Performance-48.85%-5.23%33.77%23.47%

Veradigm Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDRX
Veradigm
2.1747 of 5 stars
$4.68
-1.5%
$13.00
+177.8%
-49.8%$506.68M$1.53B0.008,000Positive News
OMCL
Omnicell
3.6103 of 5 stars
$30.42
+2.2%
$45.33
+49.0%
-20.5%$1.39B$1.11B60.843,670Earnings Report
HSTM
HealthStream
4.3559 of 5 stars
$26.05
+1.6%
$31.50
+20.9%
-6.7%$782.97M$291.65M41.351,093News Coverage
Earnings Report
Dividend Announcement
Analyst Forecast
CRTX
Cortexyme
N/A$1.68
-0.6%
N/A+140.6%$50.65MN/A-0.5755
CNGL
Canna-Global Acquisition
N/A$10.74
flat
N/AN/A$70.99MN/A0.002
OMQS
OMNIQ
N/A$0.10
flat
N/A-41.3%$1.02M$81.19M-0.04190Gap Up
KBNT
Kubient
N/AN/AN/A-50.0%$1K$1.17M0.0040
BLIV
Belive
N/A$2.53
+7.7%
N/AN/A$0.00$1.85M0.0034Gap Up
DAIC
CID Holdco
N/A$5.30
+12.3%
N/AN/A$0.00$290.47K0.00N/A
SAIC
Science Applications International
3.1434 of 5 stars
$113.21
+2.2%
$125.64
+11.0%
-2.6%$5.31B$7.51B19.0926,000Positive News
RAMP
LiveRamp
4.7022 of 5 stars
$32.56
+1.8%
$41.29
+26.8%
+3.2%$2.08B$745.58M-3,256.401,300Trending News
Earnings Report
Analyst Forecast
Gap Down

Related Companies and Tools


This page (NASDAQ:MDRX) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners